2022
Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B)
Sperber P, Gebert P, Broersen L, Huo S, Piper S, Teegen B, Heuschmann P, Prüss H, Endres M, Liman T, Siegerink B. Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B). Journal Of Neurology 2022, 269: 5521-5530. PMID: 35718820, PMCID: PMC9468072, DOI: 10.1007/s00415-022-11203-x.Peer-Reviewed Original ResearchConceptsSeronegative patientsIschemic strokeCognitive functionNMDAR1-ABLow titersHigh titersFavorable cognitive outcomeModerate ischemic strokeAntibody seropositivityProspective cohortReceptor antibodiesSerum titersPatientsSeropositivityCognitive statusStrokeTelephone interviewsInverse probabilityTitersCognitive outcomesCell-based assaysTICSLong termSerostatusResultsData
2019
Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B)
Sperber P, Siegerink B, Huo S, Rohmann J, Piper S, Prüss H, Heuschmann P, Endres M, Liman T. Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B). Stroke 2019, 50: 3213-3219. PMID: 31526121, DOI: 10.1161/strokeaha.119.026100.Peer-Reviewed Original ResearchConceptsSecondary vascular eventsFunctional outcomeVascular eventsHigh titersNMDAR1-ABSeronegative patientsSeropositive patientsFirst strokeLong-term clinical outcomesLong-term functional outcomeCombined end pointRecurrent vascular eventsOutcomes of patientsPoor functional outcomeSub-group analysisOutcomes of interestAnti-NMDAAutoimmune encephalitisCardiovascular riskProspective cohortRankin ScaleHazard ratioClinical outcomesNeuroprotective effectsReceptor antibodies